StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ARTV yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $11.38 | $10.68 | -6.15% | 0.4M |
| 05-15 | $10.60 | $9.78 | -7.74% | 0.5M |
| 05-18 | $9.96 | $9.22 | -7.43% | 0.5M |
| 05-19 | $9.21 | $8.55 | -7.22% | 0.8M |
| 05-20 | $8.84 | $7.84 | -11.31% | 1.1M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 |
|---|---|---|---|
Revenue | $32.92M | $31.14M | $4.49M |
Operating Income | $-30.67M | $-18.70M | $-29.51M |
Net Income | $-28.72M | $-16.72M | $-11.28M |
EPS (Diluted) | $-35.78 | $-20.89 | $-35.12 |
Total Assets | $105.11M | Not available | Not available |
Total Liabilities | $50.72M | Not available | Not available |
Cash & Equivalents | $53.50M | $65.89M | $53.70M |
Free Cash Flow OCF − CapEx | $-50.69M | $-39.38M | $-28.45M |
Shares Outstanding | 802.75K | 800.54K | 797.40K |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.